BioMed Research International / 2018 / Article / Tab 1

Review Article

Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention

Table 1

Baseline characteristics of trials comparing dual therapy with triple therapy after PCI.

Study/authorDesignYearNumber of patientsMale (%)TTDTFollow-up (months)Indication for PCIINRIndication for anticoagulation

RE-DUAL PCI [31]RCT2017272576%w + a + c, w + a + t + (c or t) [44%], d + (c or t) [56%]14ACS, CAD2.0–3.0AF

De Vecchis et al. [33]20169845%w + a + cw + c [NR], w + a [NR]12ACS, CADNRAF, mechanical valve, VTE, dilated cardiomyopathy

PIONEER [12]RCT2016141574%w + a + c [96%], w + a + p [1%], w + a + t [3%]R + c [93%], R + p [2%], R + t [5%]12ACS, CAD2.0–3.0AF

ORBIT-AF [34]2016182772%w + a + c, w + a + p, d + a + c, d + a + pw + a [NR], w + c [NR], w + p [NR], d + a [NR], d + c [NR], d + p [NR]24CADNRAF

AFCAS [24]201491470%w + a + cw + c [100%]12ACS, CAD1.8–3AF

WARSTENT [25]201440126%w + a + cw + c [NR], w + a [NR]12ACS, CAD1.8–4.5AF, apical thrombus, apical akinesis, VTE, mechanical valve

Braun et al. [35] 201526677%w + a + cw + t [100%]3ACS2.0–3.0AF, apical thrombus, apical akinesis, VTE, mechanical valve

Lamberts et al. [36]20131216561%w + a + cw + c [27%], w + a [73%]12ACS, CADNRAF

WOEST [9]RCT201357380%w + a + cw + c [100%]12ACS, CAD2AF, mechanical valve, VTE, apical aneurysm, PAD, EF < 30%

Rubboli et al. [37]201263273%w + a + cw + a [100%]12ACS, CADNRAF, VTE, mechanical valve, dilated cardiomyopathy, ischemic heart disease, cardiac thrombus, CVA, LV aneurysm, biological heart valve

Persson et al. [38]2011117776%w + a + cw + c [45%], w + a [55%]12ACSNRNR

Gao et al. [39]201062271%w + a + cw + c [87%] or w + a [13%]12ACS, CAD1.8–2.5AF

MUSICA [40]200940581%w + a + c, LMWH + a + cw + c [80%], LMWH + c [4%], w + a [13%], LMWH + a [2%]6ACS, CADNRAF, mechanical valve, CVA

Sørensen et al. [41]20094081263%w + a + cw + c [0.5%], w + a [2%]18ACSNRNR

GRACE [26]200780070%w + a + cw + c [51%], w + a [49%]6ACSNRAF, STEMI, VTE, mechanical valve

Karjalainen et al. [42]200723974%w + a + cw + c [58%], w + a [42%]12ACS, CAD2–2.5AF, mechanical valve, VTE, CVA

a = aspirin; ACS = acute coronary syndrome; AF = atrial fibrillation; c = clopidogrel; CAD = coronary artery disease; CVA = cerebral vascular accident; d = dabigatran (110 mg BID); = dabigatran (150 mg BID); DT = dual therapy; LMWH = low molecular weight heparin; NR = not reported; p = prasugrel; = prospective trial; PAD = peripheral artery disease; R = rivaroxaban; = retrospective trial; RCT = randomized-control trial; t = ticagrelor; TT = triple therapy; VTE = venous thromboembolism.